Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
We are a commercial-stage biotech company focused on harnessing the inherent biolo...
We are a commercial-stage biotech company focus...
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
Apollo Endosurgery, Inc. is a medical device company focused on less invasive ther...
Apollo Endosurgery, Inc. is a medical device co...
Heat Biologics a biopharmaceutical company that develops immunotherapies with the ...
Heat Biologics a biopharmaceutical company that...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing thera...
At Catabasis Pharmaceuticals, our mission is to...
Join the National Investor Network and get the latest information with your interests in mind.